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The success of Fc-fusion bio-therapeutics has spurred the development of other Fc-fusion products for
treatingand/or vaccinating againstarangeofdiseases. Wedescribeamethod tomodulatetheir functionby
converting them into well-defined stable polymers. This strategy resulted in cylindrical hexameric
structures revealed by tapping mode atomic force microscopy (AFM). Polymeric Fc-fusions were
significantlylessimmunogenicthantheirdimericormonomericcounterparts,aresultpartlyowingtotheir
reduced ability to interact with critical Fc-receptors. However, in the absence of the fusion partner,
polymeric IgG1-Fc molecules were capable of binding selectively to FccRs, with significantly increased
affinity owing to their increased valency, suggesting that these reagents may prove of immediate utility in
the development of well-defined replacements for intravenous immunoglobulin (IVIG) therapy. Overall,
thesefindingsestablishaneffectiveIgGFc-fusionbasedpolymericplatformwithwhichthetherapeuticand
vaccination applications of Fc-fusion immune-complexes can now be explored.
P
roteintherapeuticshasrecentlyemergedasasignificantclassofhighlyeffectivepharmaceuticals,andwithin
thisgroup,Fc-basedfusionproteins,inwhichtheFcdomainofanantibody(Ab)oftheIgGisotypeisjoined
to a different protein, are considered among those with the greatest promise
1,2. Already with demonstrable
successes
1,2, their effectiveness is commonly believed to be owing to interactions with specific effector proteins,
such asthe salvagereceptor FcRnthatincreasesserum half-lifeandprolongstherapeutic activity
3,4.Similarly, the
Fc region of Abs is increasingly being explored as an Ag delivery vehicle in adjuvants for the induction of
protective immunity or tolerance owing to their ability to activate specific FccRs that trigger activating and/or
inhibitory signalling pathways that set thresholds for well-balanced immune responses
5. However, existing
approaches that use the Fc to deliver Ag to immune cells have one major drawback that stems from their
monomeric structure, namely an inability to cross-link multiple FccRs with the high affinity required for
enhanced cell signalling.
Inparticular,monomericFc-fusionsbindwithnegligibleaviditytokeylow-affinityFccRs,includingFccRIIA,
FccRIIB,andFccRIIIthatarecrucialtoinitiatingprotectiveimmuneresponses
6,7.MostFccRs(withtheexeption
of FccRI) can only interact with high avidity to Abs that are presented to the immune system as immune
complexes (ICs).Several studieshave shownthatICsarepotentactivatorsofdendritic cells (DCs)andcanprime
stronger immune responses than Ag or Ab alone
8–12. Importantly, FccR-dependent IC internalization not only
results in MHC-class-II-restricted Ag presentation, but also in cross-presentation on MHC class I molecules,
thereby priming both CD4
1 and CD8
1 T-cell responses
8. The magnitude of these responses are controlled and
enhanced in part by FcRn
13, but also by the inhibitory FccRIIB, as DCs derived from FccRIIB-knock out mice
generate stronger and longer-lasting immune-responses in vitro and in vivo
14,15. More importantly, FccRIIB-
deficient DCs, or DCs incubated with a mAb that blocks IC binding to FccRIIB, show a spontaneous matura-
tion
16,17, suggesting that the inhibitory FccRIIB not only regulates the magnitude of cell activation, but also
actively prevents spontaneous DC maturation under non-inflammatory steady-state conditions
16,17.
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SCIENTIFIC REPORTS | 1 : 124 | DOI: 10.1038/srep00124 1Thus,ithasbeenalongsoughtgoalofbiosyntheticimmunologyto
develop a strategy to efficiently couple monomeric IgG Fc-fusion
proteins into polymeric ICs so as to take advantage of the existing
intrinsic host pathways optimized for native ICs. While native ICs
can contain many Fc domains owing to the binding of many Abs to
the same antigenic complex, this means of multimerization is not
possible with Fc-fusions owing to the covalent linkage of the Ag to
the Fc domain. Here, instead, we use the knowledge of how IgM
polymerizes via their Fc domains to develop a novel approach for
generatingrecombinantpolymericFc-fusionproteins(Figure1).We
show that this strategy is effective with a human IgG1-Fc subclass
and results in a significantly increased affinity (improved binding),
likely resulting from the increased avidity, for both FccRs and FcRn.
Yetwealsoidentifyasurprisingdependenceofthisinteractiononthe
fusion partner, which provides useful guidance for future develop-
ments. Finally we characterize the immunogenicity and immunoto-
lerance of these first-generation constructs in mouse models of
malaria and schistosomiasis, and identify properties that require
further development to more fully meet their vaccination potential.
Nonetheless, we identify a number of constructs that for certain
clinical applications, in particular IVIG therapy, would have signifi-
cant advantages over existing strategies and thus could be of imme-
diate benefit. Thus in total, this work provides a generally applicable
strategytoconstruct polymeric IgGFc-fusions withwhichthe thera-
peutic and vaccination potential of recombinant ICs can now be
investigated.
Results
Production of Fc-fusion proteins. To first establish a general
framework with which polymeric Fc-fusion proteins can be
produced to high yield, we first developed procedures for the
production of monomeric Fc-fusions. In particular, we fused the
Fc of human IgG1 (hIgG1) or mouse IgG2a (mIgG2a) to a wide
variety of proteins and glycoproteins (See supplementary Table S1
online), including the 19 and 42 kDa subunit Ags from Plasmodium
falciparum (Pf)o rPlasmodium yoelii (Py) merozoite surface protein
Figure 1 | Hexameric Fc-fusions and their structural characterization (a)
Schematic diagram illustrating the novel approach by which Fc-fusion
proteins can be polymerized. Attaching the C-terminal IgM tailpiece and
mutatingLeu309toCystoenableformationofinter-monomericdisulfide
bridges produces well-defined hexameric Fc-fusion complexes. (b)
Molecular modelofthe hexamericPfMSP119-hIgG1Fc-TP-LH309/310CL.
After first energy minimizing the monomer, the hexameric model was
constructed by rotating each monomer by multiples of ,60u, keeping the
C309 residues (here C207) within a common plane, followed by linking
together neighboring monomers by these cysteines and minimizing the
energy and equilibration. Shown are top and side views of the hexamer
with the C309 and tailpiece cysteine (here, C366) residues as yellow vdW
spheres.TheC309residuesinneighboringmonomersarecovalentlylinked
to each other in this model. The tailpiece cysteines in randomly selected
monomers were also joined together. The tailpieces are shown in red, the
Fc of hIgG1 in blue, and PfMSP119 in orange. (c) AFM images of
PfMSP119-hIgM-Fc reveal star-shaped, six-fold symmetric complexes. At
larger scan sizes (top panel), the sample shows a uniform population of
circularcomplexes.Atsmallerscansizes(lowerpanel),thesecomplexesare
shown to consist of a central protrusion ,20nm in diameter, around
which are arranged predominantly six, symmetrically disposed smaller
radial projections. The scale bar in the top panel is 200nm and each of the
images in the lower panel is 75375nm
2. (d) AFM images of hIgG1-Fc-
LH309/310CL-TP show structures consistent with hexameric complexes.
The larger scan size image (top panel) shows a highly uniform population
of circularly shaped complexes. The smaller scan sized images show these
complexes to consist of a circular structure that is similar in diameter and
height to the central protrusion of the PfMSP119-hIgM-Fc hexamers, as
expected for hexameric Fc-fusion complexes without the fused partners.
The scale bars in the top and lower panels are 200nm and 50nm,
respectively.
www.nature.com/scientificreports
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lines widely used for good GMP-production of therapeutic Abs by
the pharmaceutical sector. These cells expressed good yields of the
Fc-fusions that were exported from the cell, allowing for easy and
cost-effective purification on protein-G sepharose columns to which
the proteins were bound. These Fc-fusion proteins all ran as
monomers by size-exclusion chromatography (SEC) and Western
blotting (See supplementary Fig.1 online).
Difficulties in manufacturing native ICs have limited studies of
their therapeutic and vaccination potential applications. In particu-
lar, natural ICs are both ill-defined (ratio of the Ab5Ag for use) and
unstable, both of which are significant obstacles for any systematic
investigation. We sought to overcome these shortcomings by engin-
eering the monomeric Fc-fusions into recombinant ICs as depicted
in Fig. 1A. It has been shown that the 18 amino acids located at the
carboxyl-terminus of human IgM (hIgM) are involved in polymer
assembly, as this single modification has been shown to generate
large hIgG polymers with increased effector function
18. We added
the18aminoacidtailpiece(-tp)fromhIgMtogetherwitha5amino-
acid linker to the C-terminus of the human and mouse IgG Fc-
fusions. However, in the context of Fc-fusions studied here, this
single modification did not induce polymerization of either the
hIgG1-Fc or mIgG2a-Fc backbones, which were expressed entirely
as monomers (See supplementary Table 1).
Previously, we demonstrated the importance of a cysteine residue
at position 309 for the formation of polymeric Abs
19,20. The homo-
logous Cys414 in hIgM is known to form inter-monomeric disulfide
bridges that are critical for its polymerization into large molecular
weightcomplexes,which,intheabsenceofJchain(asisthecasewith
the CHO-K1 cells), are hexamers. We therefore used site-directed
mutagenesis to introduce this mutation into the equivalent position
in the -tp containing monomeric Fc-fusion proteins. We also
mutated the neighboring His310 to Leu, since a histidine at this
position might have inhibited polymeric assembly by interfering
with disulphide bridge formation. This final modification allowed
the hIgG1 based Fc-fusions to polymerize into molecules of
,540 kDa when analyzed by SEC or western blotting (See supple-
mentaryFig. 2online),andbycomparisonwiththehIgM-Fcfusions
whichactedascontrolsforpolymerization(SeesupplementaryFig. 3
online). A molecule of this size would represent a hexameric con-
formation of the Fc-fusion protein as shown in Fig. 1. We also
observed a protein of ,160 kDa that likely represents a dimeric
conformation of the hIgG1-based construct (See supplementary
Fig. 2 online), since it too was detected by immunoblotting with
Fc-specific reagents (See supplementary Fig. 2 online). When the
polymeric Fc-fusion constructs are expressed in the absence of Ag,
we observed proteins of ,312 and ,100 kDa consistent with these
also being expressed as hexameric and dimeric entities (See supple-
mentaryFig. 2online).Interestingly,thesesamemodificationsinthe
mIgG2a backbone failed to allow us to purify anything larger than
a dimer by protein-G affinity chromatography. There was no
obvious degradation of PfMSP119-hIgG1-Fc-LH309/310CL-TP or
the PyMSP119-hIgM-Fc after long-term storage (.4 months) at
either 4uCo r220uC, which was confirmed by SEC and SDS-
PAGE gel analysis.
Structure of hexameric Fc-fusion proteins. To determine if a
hexameric architecture could be accomodated by the human IgG1-
Fc backbone when fused to Ag, we modelled the PfMSP119-hIgG1-
Fc-LH309/310CL-TP hexamer following principles similar to those
applied with the recently determined structure of polymeric hIgM
21.
Fromthismodel,itisapparentthatamoleculeaslargeasthe19 kDa
PfMSP119 Ag could easily be accomodated within this polymeric
platform (Figure 1b). Furthermore, analysis of this model confirms
that the protein G, FcRn and FccR binding sites would not be
occluded with this polymerization (See supplementary Fig. 4
online). These hexamers, however, did exhibit some flexibility in
the lower hinge region, at the junction of Ag attachment, as might
be expected for this region, which could influence the binding of
receptors.
Todirectlycharacterizethesizeandmorphologyofthehexameric
Fc-fusions, we imaged PfMSP119-hIgM-Fc and hIgG1-Fc-LH309/
310CL-TP constructs with tapping mode AFM under solution.
HexamericPfMSP119-hIgG1-Fc-LH309/310CL-TPcomplexesfailed
to bind to mica substrate with sufficient strength to withstand the
lateralforcesimpartedbythescanningtip,eveninthetappingmode.
As shown in Fig. 1C, both polymeric fusion complexes form ahighly
uniform population of well-defined structures. With the PfMSP119-
hIgM-Fcpolymers,theAFMimagesrevealacentralprotusion(206
3nm(n546)indiameter,5.860.5nm(n552)inheight)surrounded
by predominantly six, hexagonally arranged, smaller radial projec-
tions, consistent with the expected hexameric architecture of these
proteins and previous cryo-AFM images of native IgM
21. With the
hIgG1-Fc-LH309/310CL-TP construct (Figure 1d), the AFM images
show the complexes as cylindrical structures (18 6 2nm (n551) in
diameter, 5.7 6 0.4nm (n554) in height), similar to the dimensions
of only the central protrusion in the hIgM-Fc hexamers. These
images are also consistent with the dimensions predicted from the
aforementioned modelling analysis (Figure 1B). Thus, overall, these
direct images of the constructs verify that these IgG Fc-fusions are
well-folded and readily self-assembled into predominantly hexame-
ric polymers.
Binding to FccRs. Since native ICs are functionally distinguished
from monomeric Fc-fusions by a significantly higher affinity for
many FccRs, we tested whether these recombinant ICs would
show a likewise stronger affinity for these receptors relative to their
monomericcounterparts. ThemonomericFc-fusionsproducedhere
boundtobothhuman (Figure 2a)andmouseFccRs (Figure2b) with
the low affinity expected of monomers. Unexpectedly however, the
natureofthemoleculefusedtotheFcmarkedlyaffectedtheabilityof
the monomeric Fc-fusions to interact with some of the FcRs. In
particular, while all of the fusions bound to both human and
mouse high affinity FccRI with only minor differences in affinity,
the hIgG1-Fc fusion to the large 42 kDa Ag (PyMSP142-hIgG1-Fc)
bound to hFccRIIA
H131 and hFccRIIIA/B, while the smaller 19 kDa
PfMSP119-hIgG1-Fc fusion bound poorly to both receptors. The
reasons for these differences are not clear, but it does indicate a
property that must be taken into consideration in the future design
of monomeric Fc-fusions.
With the polymeric Fc-fusions, in stark contrast to either the
monomeric PfMSP119-hIgG1-Fc (Figure 2) or the dimeric
PfMSP119-hIgG1-Fc-LH309/310CL-TP (which bound hFccRI,
hFccRIIA
R131, hFccRIIA
H131, hFccRIIB, but not FccRIIIA/B), the
hexameric PfMSP119-hIgG1-Fc-LH309/310CL-TP bound only
weakly to hFccRI and was unable to bind to any of the other human
or mouse FccRs (Figure 3). However, this lack of binding to FccRs
wasdue tothepresence ofthePfMSP119,sincehexameric hIgG1-Fc-
LH309/310CL-TP bound very well to all of the FccR investigated
here (Figure 3). In fact, the hIgG1-Fc-LH309/310CL-TP hexamers
bound with a log-order higher affinity to hFccRI and hFccRIIA
R131,
as expected from its increased valency (Figure 3 and supplementary
Fig. 5 online). Also in contrast to hIgG1-Fc monomers, there was
marked binding of the hexameric hIgG1-Fc-LH309/310CL-TP to
both inhibitory human and mouse FccRIIB (Figure 3). Overall then,
these results thus indicate that this means of polymerization pro-
duces complexes that can indeed exhibit the high affinity for FccRs
characteristic of native ICs.
Binding to the neonatal FcRn. We next investigated the ability of
the monomeric Fc-fusions to interact with the neonatal FcRn, which
is responsible for maintaining the long half-life of Abs in the
circulation. The monomeric hIgG1 Fc-fusions interacted almost
www.nature.com/scientificreports
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SPR analysis (Figure 4a). The murine PfMSP119-mIgG2a-Fc bound
only weakly to the human FcRn, in contrast with the human based
Fc-fusions that bound with higher affinity to the mouse FcRn
(Figure 4b), and in all cases binding only occurred at pH6.0, as
expected from previous observations
22.
With the polymers, similar to the observations with FccRs, hex-
americ PfMSP119-hIgG1-Fc-LH309/310CL-TP failed to bind to
either hFcRn or mFcRn, in contrast to the dimer PfMSP119-hIgG1-
Fc-LH309/310CL-TP which bound weakly to hFcRn and more
strongly to mFcRn as determined by SPR analysis (Figure 5). In
the absence of the MSP119 Ag, the hexameric hIgG1-Fc was capable
of binding mFcRn but not hFcRn suggesting that the presence of the
Ag also markedly affected binding to FcRn across species (Figure 5).
The half-life of PfMSP119-hIgG1-Fc-LH309/310CL-TP was signifi-
cantly shorter (,18h) than for IVIG (predominantly monomeric
IgG) when injected i.p. into mice, a result that was predicted from
the lack of binding of PfMSP119-hIgG1-Fc-LH309/310CL-TP to
mFcRn (See supplementary Fig. 6 online).
Binding to complement. Because natural ICs may activate
complement, we also investigated the ability of PfMSP119-hIgG1-
Fc-LH309/310CL-TP hexamers and dimers to bind C1q and
activate the classical complement pathway (See supplementary
Fig. 7). Hexamers bound C1q poorly compared to dimers, which
in turn bound less well than intact monomeric IgG, a gradation
reflected in comensurate decreases in detection of the C5-9
terminal complex. The absence of Ag did not markedly improve
binding of either dimer or hexamer to C1q (data not shown), and
bothC1qbindingandC5-9depositionwerenegligibleforthecontrol
IgA Ab (See supplementary Fig. 7). Taken together with the lack of
bindingtoFccRs,thereducedcomplementactivationseeninthesein
vitro experiments is supported by the complete lack of an Arthus
reaction,atypeIIIhypersensitivityreactioninitiatedbyICformation
at the site of inoculation, even when PfMSP119-hIgG1-Fc-LH309/
310CL-TP was administered with alum (see Immunization with Fc-
fusion proteins).
Enhanced binding of polymeric hIgG1 Fc-fusions to B cells. As a
first step to evaluate the interaction of these polymeric Fc-fusions
with immune cells involved inAg presentation, weinvestigated their
ability to bind to CD19
1 B cells by FACS analysis. Since these cells
only express FccRIIB
5–7, we expected that hexameric PfMSP119-
hIgG1-Fc-LH309/310CL-TP would bind less strongly than the
corresponding dimers, in accordance with the aforementioned
ELISA and SPR results. However, as shown in (Figure 6), the
hexamers were found to bind to a greater degree to these CD19
1 B
cellsthanthedimers.Thus,theresultsindicatethatthereisareceptor
onthesecells(notFccRIIB)thatinteractswithpolymericPfMSP119-
hIgG1-Fc-LH309/310CL-TP constructs, and further suggests that
the greater affinity for this unidentified receptor for the hexamers,
is owing to its greater valency.
Figure 2 | Binding of monomeric Fc-fusions to human and mouse FccRs. Titrated amounts (50–0.3 nM) of Fc-fusion proteins were coated onto ELISA
wellsasdescribed in methods. Binding ofGST-fused (a)human and (b) mouse FccRsas indicated werevisualized using an HRP-conjugatedanti-GSTAb.
(¤) 5PfMSP119-hIgG1-Fc,(%) 5PyMSP142-hIgG1-Fc,and($)5PfMSP119-mIgG2a-Fc.Thevaluesrepresenttheaverageoftriplicatedeterminations.
www.nature.com/scientificreports
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these first generation recombinant ICs exhibit similar properties as
native ICs with respect to their interaction with known effector
systems, we sought to evaluate their immunogenicity by testing
these constructs for their efficacy in producing protective
immunity in mouse models of malaria. The monomeric Fc-fusions
induced antigen (Ag)-specific IgG1 responses when injected into
mice (See supplementary Table 1 & supplementary Fig. 8 online).
Figure 3 | Binding of polymeric Fc-fusions to human and mouse FccRs. Titrated amounts (50–0.3 nM) of Fc-fusion proteins were coated onto ELISA
wells. Binding of GST-fused (a) human and (b) mouse FccRs receptors as indicated were visualized using an HRP-conjugated anti-GST Ab. (&) 5
hexamer PfMSP119-hIgG1-Fc-LH309/310CL-TP, (m) 5 dimer PfMSP119-hIgG1-Fc-LH309/310CL-TP, and (.) 5 hIgG1-Fc-LH309/310CL-TP. The
values represent the average of triplicate determinations.
Figure 4 | Binding of monomeric Fc-fusions to human and mouse FcRn. Representative sensograms showing binding of 100 nM of each Fc-fusion
variant injected over immobilized (a) hFcRn or (b) mFcRn at pH 6.0 or pH 7.4. The experiments were performed at 25uC with a flow rate of 20 ml/min.
www.nature.com/scientificreports
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fusedtohIgG1-FcormIgG2a-Fcinimmunizationsofeitherwildtype
or human FccRI (CD64) transgenic animals (See supplementary
Fig. 8 online), a result supported by the ability of both variants to
bind hFccRI (Figure 2a). No drammatic improvement in Ab titres
was obtained when monomeric Fc-fusions were co-administered
with clinically relevant adjuvants e.g. alum (See supplementary
Fig. 9 online), and this effect was maintained even after challenge
with parasites. Prior immunization with the monomeric Fc-fusions
also bolstered Ag-specific IgG responses by a log order during an
infection with parasites (See supplementary Fig. 10 online). Despite
high titres of MSP119-specific Ab (1510,000) all animals inoculated
withtheseFc-fusionssuccumbedfrommalariawhenchallengedwith
parasites (See supplementary Table 1 online). Routes of Fc-fusion
administration (s.c. vs i.p.) did not alter our basic findings, and
although there were dose-dependent effects on overall titres with
the PfMSP119-mIgG2a-Fc monomer administered in alum (See
supplementary Fig. 9 online), the course of the parasitemia did not
significantly alter with different levels of Ab (See supplementary
Table 1 online).
ItshouldbenotedthatweobtainedsimilarAg-specificAbtitresto
those seen with the PfMSP119-mIgG2a fusion using a monomeric
mIgG2a-Fc fusion to the S. mansoni cercarial elastase (CE) Ag, a
molecule that like MSP119 is non-immunogenic in its native form
(See supplementary Table 1 & supplementary Fig. 11 online)
23.I n
thepresence ofalum,immunizationwithahistidine-taggedCE(CE-
His) construct generated consistently higher titres of CE-specific
mIgG (all subclasses) compared to the CE-mIgG2a-Fc-fusion,
Figure 5 | Binding of polymeric Fc-fusions to human and mouse FcRn. Representative sensograms showing binding of 100 nM of each Fc-fusion
variant injected over immobilized (a) hFcRn or (b) mFcRn at pH 6.0 or pH 7.4. The experiments were performed at 25uC with a flow rate of 20 ml/min.
Figure 6 | Binding of polymeric Fc-fusions to CD19
1 human B-lymphocytes. (a) Characteristic FACs plot showing different populations of human
leucocytes represented by their forward (FSC) and side (SSC) profiles. (b) Individual CD19
1 B-lymphocytes stained with anti-human CD19-FITC
(shown by blue dots) were gated. (c)Binding of 40 mg ofhexameric (blue trace) and dimeric (green trace) PfMSP119-hIgG1-Fc-LH309/310CL-TP to the
gated human CD19
1 B lymphocytes was detected using phycoerythrin (PE)-labeled goat (Fab92) anti-hIgG. No binding was detected with the
phycoerythrin(PE)-labeledgoat(Fab92)anti-hIgGintheabsenceofFc-fusionproteins(redtrace).Dataarerepresentativeofthreeseparateexperiments.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 124 | DOI: 10.1038/srep00124 6suggesting that the presence of the Fc is tolerogenic. Although the
CE-His induced notable levels of IgE, no IgE whatsoever was detect-
able in the CE-mIgG2a-Fc-fusion immunized animals, showing that
the presence of the mIgG2a-Fc, even in the context of adjuvant, was
preventing an Ag-specific IgE response. As observed for the
PfMSP119-IgG2a-Fc-fusion, immunization of mice with CE-
mIgG2a-Fc drove a strong IgG1 response, and like the malaria
model, immunization with CE-mIgG2a-Fc-fusions did not protect
animals from a challenge infection with the cercariae parasites
(See supplementary Table 1 online). This trend to generate mIgG1
responses was seen with all the Fc-fusions irrespective of Ag, since
a fusion to enhanced green fluorescent protein also induced
mIgG1 (See supplementary Fig. 12 online). Therefore the Fc-scaf-
fold, and not the Ag tagged to it, is critical for driving the skewed
IgG1 responses observed in animals inoculated with the various
Fc-fusions.
We next examined the immunogenic properties of the purified
hexamer and dimer in immunization and challenge experiments
with malaria parasites. We observed significantly lower PfMSP119-
specific (Figure 7a,b), and a complete absence of anti-hIgG1-Fc
(Figure 7c) responses from the hexamer. Immunization of the ani-
mals with either the hexameric or dimeric PfMSP119-hIgG1-Fc-
LH309/310CL-TP drove mIgG1 responses as seen with all the Fc-
fusionmonomers (Seesupplementary Table 1online).Although the
PfMSP119-hIgG1-Fc-LH309/310CL-TP did bind weakly to hFccRI
(Figure 3), experiments in hFccRI (involved in phagocytosis of ICs)
transgenic mice were not significantly different to wildtype litter-
mates, suggesting that the poor Ab-titres observed with PfMSP119-
hIgG1-Fc-LH309/310CL-TP are not mediated primarily via hFccRI
(Figure 7a), but by a more general inability to interact with FccR,
FcRn and C1q. No improvement in Ag-specific Ab-titres, or resolu-
tion of malaria, were seen when immunizations with hexamer were
Figure 7 | PlasmodiumfalciparumMSP119-specificIgG1Abtitresinducedbyimmunizationwithhexameric ordimericPfMSP119-hIgG1-Fc-LH309/
310CL-TP. (a)Groupsofmiceimmunizedwith3dosesof10 mg/animalatfortnightlyintervalsintheabsenceofadjuvant.Experimentswereundertaken
in hFccRI transgenic BALB/c mice or their non-transgenic BALB/c control littermates (WT). (b) A repeat experiment using 4 animals per group and a
totaldoseof75 mg/animalofeitherhexamerordimerina151volumewithAlumorPBS,inthehFccRItransgenicBALB/Cmice.(c)Mouseanti-human
IgG1 responses from mice immunized with monomer, dimer, hexamer or PBS. Each point represents the mean optical density (1/2SD) of duplicate
wells for each mouse within a given group. Mann Whitney test comparing dimer vs hexamer vaccinated animals; ** 5 P,0.0001, * 5 P,0.05.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 124 | DOI: 10.1038/srep00124 7repeated in the presence of alum (Figure 7b and Supplementary
Table 1 online).
Discussion
We have developed a broadly effective strategy to polymerize mono-
mericFc-fusionproteins intowell-defined hexameric polymersso as
to modify the functional consequences of their interactions with
effector systems. These hexameric constructs were indeed found to
bind to key FccRs differently than their monomeric and dimeric
counterparts, though the strength of this interaction with the recep-
tors was found to be dependent on the fusion partner. Beyond iden-
tifying this critical property for future development, we also identify
constructs that for certain clinical applications would likely have
significant advantages over existing strategies.
This dependence of the Fc-fusion-FccR interaction strength on
the fusion partner was unexpected, but was also observed with some
of the monomeric-Fc-fusion-FccR interactions as well. With the
monomeric Fc-fusions, the interaction with hFcRn, hFccRI, and
hFccRIIA
R131 was not significantly different whether the PyMSP142
Ag or the PfMSP119 Ag was attached, but the interaction with
hFccRIIA
H131 and hFccRIIIA/B was markedly different between
these two fusions. The similar interaction with the former set indi-
catesthateachoftheFc-fusionsisproperlyfolded(asfurtherdemon-
strated in supplemental Fig. 1), and suggests that the observed
differences are owing to unique properties of the particular Ags
and to different sensitivities of the receptors for these properties.
The binding site for hFcRn on IgG is localized within the Cc2-Cc3
junction, while the binding site on IgG for the FccRs localizes to the
amino-terminal region of the Cc2 domains, within the lower hinge
region
24,25. Thus, the differences in affinity with the different Ags are
likely owing to subtle differences in the attached Ag structure in the
immediate vicinity of the lower hinge region to which the different
FccRs exhibit different sensitivities. It might thus be possible to
exploit this sensitivity with different Ags to produce Fc-fusion pro-
teinswhichexhibitevengreaterspecificityinreceptoractivation.The
tremendous impact of the type of fused Ag on binding to FccRs and
FcRn,independentoftheconstantFcscaffold,highlightstheimport-
ance of considering such binding effects for each individual Fc-
fusion.
WiththepolymericFc-fusions,whilethedimericfractionwiththe
PfMSP119 Ag interacted significantly with all of the hFccR investi-
gated here as well as hFcRn, the corresponding hexameric fraction
bound poorly to all of these receptors with the exeption of the high
affinity hFccRI which bound weakly (Figure 3). These hexamers
however clearly bound protein G (during purification) and were
recognized by Ag-specific and Fc-specific Abs (See supplementary
Fig. 2 online), indicating that, as with the monomers, these hexame-
ric Fc-fusions were properly folded, a finding supported by the SEC
andAFManalyses(Fig.1).Thelackofaffinityforthesereceptorswas
thuslikelyowingtothefusedPfMSP119Ag.Indeed,intheabsenceof
this Ag, the hexameric hIgG1-LH309/310CL-TP interacted mark-
edly with hFccRI, hFccRIIA
R131, hFccRIIB, mFccRI, mFccRIIB,
mFccRIII (Figure 3), as well as with mFcRn but not with hFcRn
(Figure 5). Theselatter findings are broadly inline with observations
made for IgG1 ICs, which also bound appreciably to the low-affinity
FccRs compared to monomeric IgG1
26. As the binding site for C1q
has also been suggested to include regions within the hinge, if not
within the Fab
27, the lack of binding to C1q is probably also owing to
the fused PfMSP119 Ag. Although we are presently unsure of the
reason for this significant difference owing to the presence of the
PfMSP119 Ag in the hexameric polymer, we note that this Ag is
exceptionallynegativelycharged(SeesupplementaryFig. 13online),
and so the increased overall negative charge of the hexamer, com-
pared with the monomer and dimer, might contribute to the lower
receptor affinity. Although the in vivo half-life of the hexameric
PfMSP119-hIgG1-LH309/310CL-Fc-TPisshortened bythepresence
of the fused Ag (See supplementary Fig. 6 online), rapid or inter-
mediate clearance may also be favorable in some applications for
such constructs, as demonstrated for IgG immunoconjugates
approved for cancer imaging and therapy
28.
Althoughnotinvestigated inthepresent work,the increased avid-
ity binding to inhibitory FccRIIB observed for hexameric hIgG1-Fc-
LH309/310CL-TP and the enhanced binding of hexameric
PfMSP119-hIgG1-Fc-LH309/310CL-TP to B lymphocytes could be
of immediate benefit in the development of well-defined replace-
ments for IVIG therapy. Seventy percent of prescribed IVIG is
now used for the treatment of autoimmune inflammatory condi-
tions,includingidiopathicthrombocytopenicpurpura(ITP),instead
of as replacement therapy in patients with immune deficiency
29.
IVIG is purified from the pooled plasma of ,3,000 anonymous
donors and as a consequence of extensive screening for viruses is
expensive to make. Although the mechanisms of action for IVIG
remainunclear,themostcompellingsupportarolefortheFcportion
of Ab and interactions with both inhibitory and activating FccRs
found on monocytes and macrophages since Fc-fragments derived
fromIVIGcancurechildrensufferingfromITP
30,althoughtheexact
receptorsinvolvedarehotlydebated
31–34andmayvaryforthedisease
for which IVIG is used
35. Such beneficial effects occur rapidly in ITP
where they are unlikely to be wholly dependent on the long half-life
influenced by interactions with the FcRn
5–7. It has also recently been
shown that it is the polymeric fraction, and more specifically the
sialic acid component of IVIG that is responsible for this beneficial
effect
31,36, observations supported by the reversal of ITP in mice by
ICs or deglycosylated IVIG
32,37. It is known that IVIG binds to CD22
lectin(Siglec-2)onBlymphocytesviaaterminalsialicacidontheFc-
glycan
38, and a recent study demonstrated that sialylated Fcs are
responsiblefortheanti-inflamatoryeffectsofIVIGinamousemodel
ofarthritisasaresultoftheirinteraction withhumanlectinreceptor,
DC-SIGN, on DCs
39. Because the proportion of active multimeric
IgG and/or sialylated IgG in commercially available IVIG is extre-
mely low (, 1% and 5% respectively), very large doses of IVIG have
to be given to patients, typically 2 g per kg bodyweight, and this can
cause adverse reactions in some patients. Although the exact nature
and molecular make-up of the polymeric fraction of IgG in IVIG
preparations remains unclear, we have confirmed thatthe polymeric
Fc-fusions described here are sialylated (See supplementary Fig. 14
online). The enhanced binding of hexameric PfMSP119-hIgG1-Fc-
LH309/310CL-TP to B lymphocytes is particularly intriguing in this
regard, since this binding is not effected by FccR or FcRn. These
hexamericFc-fusionsmaythereforeclustersialicacidbindingrecep-
tors and impart protection from autoimmune disease more effec-
tively,andatlowerdosages,thancurrentlyseenwithIVIG.Although
many IVIG preparations contain dimers that arise from idiotype
(Id)/anti-Id complexes associating non-covalently through Fab
interactions
40,theymayalsocontaincovalentIgG2dimers
41,suggest-
ing that exploration of polymeric Fc-fusions on an IgG2 backbone
may be usefully investigated given that hIgG2, as with hIgG1-Fc-
LH309/310CL-TP, can interact with hFccRIIA
R131.
26,42 Although lar-
ger (.350 kDa) multimeric IgG and circulating ICs are mostly
removed in the preparation of IVIG, these are common in healthy
individuals where they can contribute as much as 10% to the overall
plasma Ab concentration (See supplementary Fig. 15 online), indi-
cating a physiological role in maintaining immune homeostasis in
these healthy individuals
43. These findings suggest that further work
nowneedstobedonewiththehexamerichIgG1-Fctodetermineifit
has potential for treating autoimmune disease, including ITP.
Most Fc-fusions are currently based on hIgG1 backbones that can
only engage with activating FccRs expressed by innate immune cells
includingphagocytes
5–7,25,26,andthereforethisclassofAbmaynotbe
the ideal scaffold for delivery of Ags to adaptive immune cells
involved in generating long term memory responses by useful vac-
cines. Indeed the Fc-fusions described here induced significant, yet
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and challenge studies with malaria parasites (See supplementary
Table 1 online). Mouse IgG1 is believed not to be a subclass assoc-
iated with protective properties as it possesses an extremely low
activation to inhibition ratio (0.1 compared to 69 and 7 for IgG2a
andIgG2b,respectively), asaconsequence ofitspreference forbind-
ing inhibitory FccRIIB receptor
44. Fusions of an unrelated Ag, cer-
carial elastase (CE) from S. mansoni, to the mIgG2a-Fc also
generated non-protective IgG1 in wild-type mice (See supplement-
ary Table 1 & supplementary Fig. 10 online) and were likewise
poorly immunogenic when compared with Ag administered in the
absence ofthe Fc. Wehave shown here thatthe presence of thefused
Ag can greatly interfere with the ability of the IgG1 polymers to
engage FccRs. Increasing the distance between the Ag and the
FccR-binding region on the Fc, for example by making fusions to
hIgG3 which has an extended hinge-region, may allow for polymers
to interact with FccRs without steric hindrance from the fused pro-
tein. Alternatively the useof smaller Ags or peptides incorporating B
and T cell epitopes may prove more effective.
In conclusion, the prevention of infectious diseases, allergies,
malignancies,fertilityandimmunedisordersbyvaccinationrequires
immune-potentiators and suitable delivery systems that together
constitute the adjuvant responsible for triggering optimal immune
responses. Here we have modified the hugely successful IgG Fc-
fusion platform for the simultaneous delivery of multiple Ags and/
orligandstotheimmunesystemthatmaymimicthe‘depot-effect’of
ICs, whilst removing the need for the vaccine formulation to be
associatedwithtoxicadjuvants.Whilenottestedhere,thismodifica-
tion is also expected to enhance the efficacy of existing Fc-based
biologicals, which have already shown tremendous promise as
monomeric constructs.
Methods
Construction of monomeric Fc-fusion vectors. Primer pairs containing EcoRI and
BglII restriction sites: 59-AATAATGAATTCCAACATTGCCCAACACCAATG-39
and 59-AATAATAGATCTGTTAGAGGAAGAACAGAAGAT-39 were designed to
amplify a codon-optimized PfMSP119from plasmid pUCPfMSP119into a TOPO TA
parking vector by polymerase chain reaction (PCR) in order to create
pTOPOTA2.1PfMSP119.T h ePfMSP119 was then sub-cloned as an EcoRI/BglII
fragment into pFUSE vectors (Invivogen) containing the hIgG1 or mIgG2a Fc to
create pFUSE-PfMSP119-hIgG1-Fc and pFUSE-PfMSP119-mIgG2a-Fc respectively.
Cercarialelastase(CE)fromSchistosomamansoniwassub-cloned frompGEXEL
45as
a BglII fragment by PCR using primer pairs 59-ATCTGGTTCCGCGTAGATCT-
ATACGTAGTGGTGA-39 and 59-AATTAAGCTGGAGATCTAATATTGG-
AGCGTACAA-39, and ligated into pFUSE-mIgG2a to create pFUSE-SmCE-
mIgG2a-Fc.EnhancedGreenFluorescentProtein(EGFP)wassub-clonedasaEcoRI/
BglII fragment from the plasmid pEGFP-C2 (BD Biosciences) by PCR using primer
pairs 59-TATAGAATTCCATGGTGAGCAAGGGCGAGGAGCT-39 and 59-
TATAAGATCTCTTGTACAGCTCGTCCATGCCGA-39 and ligated into pFUSE-
mIgG2a-TP.
ConstructionofpolymericFc-fusionvectors.TogenerateapolymericAgFc-fusion
protein, three step changes to the coding sequence of the hIgG1 Fc-portion were
made.The18amino-acidtailpiecefromhIgMwassub-clonedontotheC-terminusof
theFcportion,andanadditionalmutationintheCc2domaintoconvertresidues309
and 310 (EU numbering throughout) to cysteine and leucine respectively.In order to
insert the hIgM tailpiece sequence into the pFUSE vector, primer pairs 59-
CTAGGACCCCCCCTGTACAACGTGTCCCTGGTCATGTCCGACACAGCTG-
GCACCTGCTACTGAG-39 and 59-CTAGCTCAGTAGCAGGTGCCAGCTGT-
GTCGGACATGACCAGGGACACGTTGTACAGGGGGGGTC-39 were designed
which would, when annealed together, form a double stranded sequence with
overhangingbasesencodingaNheIrestrictionsitetoallowsub-cloningC-terminalto
the pFUSE vector. In order to maintain the reading frame of the protein encoded by
the plasmid, remove an existing stop codon, and allowing for convenient restriction
sites, an extra DNA base was inserted. The pFUSE vector was then digested with the
restriction enzyme NheI, and the hIgM tailpiece insert above ligated to create an
intermediaryplasmid.InordertoallowthehIgMtailpiecetobetranslatedaftertheFc
region, the stop codon present was mutated in a subsequent step, via site directed
mutagenesis, using the Quick Change II Kit (Stratagene, La Jolla, CA, USA) and
primers pairs 59- CTGTCTCCGGGTAAATTAGTCCTAGGACCCCCCCTG-39
and59-CAGGGGGGGTCCTAGGACTAATTTACCCGGAGACAG-39tocreatean
AvrII restriction enzyme site between the Fc region and the hIgM tailpiece. This
created the plasmid termed pFUSE-hIgG1-Fc-TP. When transfected into
mammalian cells this construct did not induce polymerization; therefore we made
additional changes to mimic hIgM by mutating the cysteine at position 309, involved
in forming a disulphide bridge between two monomers of IgM within the pentamer.
In order to better mimic the protein sequence of hIgM, primer pairs 59-
GTGGTCAGCGTCCTCACCGTCTGCCTCCAGGACTGGCTGAATGGCAAG-39 and 59-
CTTGCCATTCAGCCAGTCCTGGAGGCAGACGGTGAGGACGCTGACCAC-39 were designed to
introduce a cysteine residue at position 309, again by site-directed mutagenesis, as
before. Upon alignment of the nucleotide sequence encoding the protein sequence of
hIgM with that of human IgG1-Fc, it was decided, in addition, to replace the
neighbouring histidine residue at position 310 with a neutral leucine residue. The
finalplasmidincorporatingbothmutationsandthePfMSP119AgwasnamedpFUSE-
PfMSP119-hIgG1-Fc-TP-LH309/310CL. To verify incorporation of the desired
mutationsandtocheckforPCR-inducederrors,theentirecodingsequencesofallthe
expression vectors were sequenced.
A similar three-step strategy was used to generate pFUSE-PfMSP119-mIgG2a-Fc-
TP and pFUSE-PfMSP119-mIgG2a-Fc-TP-QH309/310CL with the following first,
second and third step primer pairs respectively, primer pair 1: 59-
CTAGGCCCCCCCTGTACAACGTGTCCCTGGTCATGTCCGACACAGCTGG-
CACCTGCTACTGAG-39 and 59-CTAGCTCAGTAGCAGGTGCCAGCTGTGT-
CGGACATGACCAGGGACACGTTGTACAGGGGGGGC-39; primer pair 2: 59-
CGGTCTCTGGGTAAATTACCTAGGCCCCCCCTGTAC-39 and 59-
GTACAGGGGGGGCCTAGGTAATTTACCCAGAGACCG-39; primer pair 3: 59-
GTCAGTGCCCTCACCGTCTGCCTCCAGG-39 and 59-
CCTGGAGGCAGACGGTGAGGGCACTGAC-39.
Construction of IgM-Fc fusions. The hIgM-Fc was amplified as a BglII/NheI
fragment by PCR using Cm2-For 59-
GTTAGATCTATTGCCGAGCTGCCTCCCAAA-39 and Cm4-Rev 59-
AGGCTAGCTGCATGCACACACAGAGC-39 primer pairs from plasmid
pUCm
19,20.ThePCRproductwasclonedinplaceofhIgG1-FcinpFUSE-hIgG1-Fc-TP
to generate pFUSE-IgM-Fc. PfMSP119 or PyMSP119 was released as an EcoRI/BglII
fragment from PfMSP119-hIgG1-Fc or PyMSP119-hIgG1-Fc and cloned into the
same restriction sites in pFUSE-IgM-Fc to form PfMSP119-IgM-Fc and PyMSP119-
IgM-Fc respectively. PyMSP142 was generated by PCR using primer pairs 59-
CGGAATTCGTCCGAAGATGCACCAGAAA-39and59-CGAATTCGATCCCAT-
AAA GCTGGAAGAACT-39 from plasmid PyMSP142, and sub-cloned as an EcoRI
fragment into pFUSE-IgM-Fc to generate pPyMSP142-IgM-Fc.
Expression, purification, and characterization of Fc-fusions. CHO-K1 cells
(European Collection of Cell Cultures) were transfected by electroporation with
plasmids and positive clones selected. The cells were grown in DMEM complete
media supplemented with 10% ultra-low bovine IgG FCS, 100 IU/ml penicillin, and
100mgml
-1streptomycin (PAA)at37uC/5%CO2.Stabletransfectantswereselectedin
medium containing 400 mgml
21 of Zeocin (Invivogen). Clones secreting Fc-fusion
proteins were detected by sandwich enzyme-linked immunosorbent assay (ELISA)
using mAbs 12.10 or 12.8 to capture PfMSP119 followed by goat anti-human IgG-Fc
(Sigma-Aldrich:A0170)orgoatanti-mouseIgG-Fc(Pierce:31439)Absconjugatedto
horseradish peroxidase (-HRP). From large-scale cultures in DMEM supplemented
with ultralow IgG containing FBS (Gibco), Fc-fusion proteins were purified on
Protein-G-Sepharose (GE Healthcare, Little Chalfont, Bucks, UK) or on anti-human
IgM agarose (Sigma). Eluted fractions from the affinity purification were pooled and
separated by size-exclusion chromatography on a high-performance Superdex-200
10/300GL column using an AKTAFPLC (GE Healthcare). Eluted fractions were
compared against known high MW gel filtration standards (Biorad). The integrity of
theproteinswasverifiedbySDS-PAGEonnative6%Tris-glycinegelsforpolymersor
NuPAGE 4–12% bis-Tris acrylamide gels for monomers, against SeeBlue2 pre-
stained molecular weight markers (Novex-Invitrogen).
SurfacePlasmonResonance(SPR)analysis.SPRexperimentswerecarriedoutusing
a Biacore 3000 instrument (GE Healthcare). Flow cells of CM5 sensor chips were
coupledwithrecombinantformsofsolublehumanormouseFcRn(hFcRnormFcRn;
, 2200–3000 RU) using amine coupling chemistry as described in the protocol
provided by the manufacturer. The coupling was performed by injecting 2 mgml
21 of
the protein in 10 mM sodium acetate pH 5.0 (GE healthcare). Phosphate buffer
(67 mM phosphate buffer, 0.15 M NaCl, 0.005% Tween 20) at pH 6.0, or HBS-EP
buffer(0.01 MHEPES,0.15 MNaCl,3 mMEDTA,0.005%surfactantP20)wasused
as running buffer and dilution buffer. 100 nM of each of the Fc-fusion proteins were
injectedoverimmobilizedreceptoratpH 6.0orpH 7.4,withaflowrateof20 ml/min
at 25 uC. Regeneration of the surfaces was done using injections of HBS-EP buffer at
pH 7.4(GEHealthcare).Inallexperiments,datawerezeroadjustedandthereference
cell subtracted. Data were evaluated using the BIAevaluation 4.1 software (GE
Healthcare).
Enzyme linked immunosorbent assays (ELISA). Microtiter wells (Nunc) were
coatedwithtitratedamountsoftheFc-fusions(50-0.3nM)inPBSorcarbonatebuffer
pH9 and incubated over night at 4 uC prior to blocking with 4% skimmed milk
(Acumedia)for1 hatroomtemperature(RT).Thewellswerewashedfourtimeswith
PBS/0.005% Tween 20 (PBS/T) pH 7.4 before addition of GST or HIS-fused hFccRI,
hFccRIIA, hFccRIIB, mFccRI, mFccRIIB diluted in 4% skimmed milk PBS/0.005%
Tween 20 (PBS/T) pH 7.4 and added to the wells. After incubation for 2 h at RT and
washing as above, an HRP-conjugated polyclonal anti-GST from goat (158000; GE
Healthcare) was added and incubated for 1 h at RT. Wells were washed as above,
100 ml of the substrate TMB (Calbiochem) was added to each well and incubated for
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450 nm using a Sunrise TECAN spectrophotometer (TECAN, Maennedorf,
Switzerland).
Flow cytometry. Human leucocytes were purified from whole blood by
centrifugation on Polymorphoprep gradients according to manufacturers
instructions. 1 3 10
5 cells were incubated with 200 ml FACs buffer (phosphate-
buffered saline, 0.2% bovine serum albumin, 5% goat serum) containing 40 mg of Fc-
fusions or buffer only as indicated for 1h at room temperature. Cells were washed
twicewithFACsbufferandincubatedfor1hat4uCwith1/500dilutionofF(ab9)2goat
anti-hIgG-Fc-phycoerythrin (PE) or goat anti-hCD19-fluorescein isothiocyanate
(FITC)-conjugated Abs (Southern Biotechnology) in 200 ml FACs buffer. After
washing with FACs buffer, cells were analyzed on a FACScan (BD Biosciences). Data
acquisition was conducted with CELLQuest software (BD Biosciences) and the
analysis performed with FlowJo version 9.1.
Ag-specific IgG subclass and Complement binding analysis. ELISA plates were
coated over night with 5 mgml
21 recombinant PfMSP119-GST, recombinant EGFP
(Biovision), native CE from cercarial transformation fluid, or 20 mgm l
21 hIgG1
diluted in carbonate buffer, pH 9.0. The next day ELISA plates were blocked in PBS-
0.5% Tween-20 containing 5% milk powder (Marvel). After three washes 100 mlo f
varying dilutions of sera in DMEM/10% FBS were added to duplicate or triplicate
wells and Ab allowed to bind for 1 h. After 3 washes in PBS-Tween-20, 100 mlo fa
151,000 dilution of goat anti-mIgG1-HRP, IgG2a-HRP, IgG2b-HRP, IgG3-HRP,
IgE-HRP or IgM-HRP (all Southern Biotech) in DMEM/10% FBS were added and
incubated for a further 1 h. After 3 washes as above, plates were developed with
3,39,5,59-tetramethylbenzidine dihydrochloride (Sigma: T3405) in phosphate citrate
buffer containing sodium perborate (Sigma: P4922). After 10 min, colour
development was stopped with 50 mlo f2 MH 2SO4 and the absorbance at 450 nm
read using an ELISA plate reader (Ultramark, Microplate Imaging System, Biorad).
C1q and C5-9 binding assays were essentially as described previously
46.
Atomic force microscopy. Stock solutions of PfMSP119-hIgM-Fc or hIgG1-Fc-
LH309/310CL-TP in 1xHBSS buffer were diluted to 10 mgml
21 in 0.2xHBSS buffer
and then directly applied to a freshly cleaved fragment of muscovite mica. After
incubatingfor20 minutes,thesamplewasrinsedextensivelywith0.2xHBSSbufferto
remove unadsorbed molecules. The samples were always under solution during
transport to and imaging within the AFM. Imagaing was performed in the tapping
mode with a Nanoscope IIIa Multimode AFM (Veeco, Santa Barbara, CA) using
silicon nitride cantilevers (NP-S, Veeco Probes, Santa Barbara, CA) with a spring
constant of 0.32 N/m in 0.5xHBSS buffer. The typical scan rate and initial oscillation
amplitudewere3Hzand20 nm,respectively,andtheappliedforcewasminimizedto
,0.1 nN. Thepiezoscanner (9 mm,D scanner, Veeco) wascalibrated using micaand
gold ruling. All images here were reproducible with different tips and different fast-
scan directions. All lateral dimensions were determined from the full-width at half
height.
Molecular modelling. The monomer was constructed from the crystal structure of
PfMSP119and the hIgG1 Fc-domain
47,48,using a random chain structure for both the
hinge and tailpiece regions. Each monomer was energy minimized before being
assembledintothehexamericcomplex.Allenergycalculationswereperformedusing
VMD/NAMD
49,50 using the CHARMM27 force field
51. NAMD was developed by the
Theoretical Biophysics Group in the Beckman Institute for Advanced Science and
Technology at the University of Illinois at Urbana-Champaign. To construct the
hexamer, we took advantage of two experimental observations: first, the
stoichiometry of the complex is finite (that is, oligomerization does not proceed
indefinitely), and second, oligomerization required the Cys309 (here, C207)
mutation. The former observation suggests that there is some physical reason
preventing further assembly, which we reasoned was owing to the complex being
ring-shaped, similar to those seen with natural IgM complexes
21. The latter
observationsuggeststhatadjacentmonomersarelinkedthroughtheseC309residues.
For these linkages to be possible in a ring-shaped complex, these residues must all lie
within a common plane, as is the case with the homologous cysteine residues in the
IgM pentamer
21. With these Fc-fusions, there are two types of oligomers that can
satisfythesecriteria:star-shaped,inwhichtheC309planeisthesameastheFc-plane,
and barrel-shaped, where the C309 plane is perpendicular to the Fc-plane. Both
models were examined to determine which produced a structure with lower energy,
subjecttooneadditionalcriterion.SincetheseFc-fusionshavenotevolvedtointeract
with each other but rather link by virtue of the mutated C309 residues, we assumed
that the monomers do not undergo significant structural changes to form these
bonds,andsoassignedanenergeticpenaltytoanysuchchanges.Thiswasachievedby
constraining the backbone atoms within a harmonic well (spring constant, 1 kcal/
mol/A ˚ 2)centeredonthepositionsoftheenergy-minimizedmonomericstructures.By
monitoring the contribution of this constraining potential to the total minimized
energy, the extent to which each monomer changed conformation from the
monomeric form could be evaluated. Without this constraint, the star-shaped and
barrel-shaped structures, evaluated at a range of initial C309-C309 distances, were of
a similar minimized energy. However with the constraint, at all distances, itwas clear
that the barrel-shaped structure required significantly fewer structural changes than
the star-shaped model to form the C309-C309 disulfide bridge. Thus, without the
constraint, the barrel-shaped structure achieves a similar minimized energy as the
star-shaped structure, but requiring fewer changes to the monomeric form. We
therefore favor a barrel-shaped structure for the hexamer. The final model was
constructed at the closest initial C309-C309 distance at which there was the smallest
degree of structural changes to the monomeric structure. These calculations were
performed without any of the tailpieces connected to other monomers. With this
minimized model, the tailpieces were connected to other, randomly selected,
monomers within the complex, and then the entire complex was solvated with TIP3
water
52, minimized, and finally equilibrated, as judged by the root-mean-squared-
deviation of the protein backbone. The electrostatic potential was calculated using
Swiss-PdbViewer
53. The results shown in supplementary Fig. 13 (online) were
calculated using the Coulomb approximation but similar results were obtained
calculating the Poisson-Boltzmann equation.
Mice, parasites and immunization schedule. Sex and age-matched groups of 4-6
BALB/Cmicefrom8weeksofage,bredunderspecificpathogen-freeconditions,were
immunized with Fc-fusions at 10 mg/dose (unless stated otherwise) administered by
sub-cutaneous (s.c.) or intraperitoneal (i.p.) injection at two week intervals on three
separate occasions, either alone or suspended with Alum (Thermo Scientific: 77161)
as a clinically relevant adjuvant, and as a baseline for efficacy of conventional
immunization strategies alone. Blood was collected by tail bleeding 2 weeks after the
last immunization and ahead of challenge with parasites in order to assess levels of
Ag-specific Ab prior to infection. Mice were challenged with 10,000 infected
erythrocytes of Plasmodium berghei transgenic for PfMSP119 as described
previously
54, or with 200 cercariae from a Puerto Rican isolate of Schistosoma
mansoni
45. To determine the in vivo half-life, groups of 4 female Balb/C mice were
injected i.p. with 300 mgo fPfMSP119-hIgG1-Fc-LH309/310CL-TP or
GammaGard
TM (Baxter Healthcare). Mice were bled at routine intervals and levels of
Fc-fusion determined by ELISA on pooled sera at a 1510 dilution against known
standards by ELISA as described above.
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